Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Material Traceability in Upstream – V 2.0

Posted on By


Biosimilars: SOP for Material Traceability in Upstream – V 2.0


Standard Operating Procedure for Material Traceability in Upstream Operations in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/134/2025
Supersedes SOP/BS/134/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define a standard procedure for ensuring complete traceability of all materials used in upstream processes during biosimilar manufacturing, from raw material receipt to final usage, in compliance with GMP guidelines.

2. Scope

This SOP applies to the warehouse, production, and quality assurance departments involved in the receipt, storage, issuance, and usage of materials such as media, buffers, supplements, and reagents in upstream biosimilar operations.

3. Responsibilities

  • Warehouse: Ensure materials are received, labeled, and stored with unique codes.
  • Production: Record issuance and usage of materials against specific batch numbers.
  • QA: Audit material records and approve traceability documentation.

4. Accountability

The Head of QA is accountable for ensuring that material traceability is maintained, reviewed, and auditable for all upstream manufacturing activities.

5. Procedure

5.1 Receipt and Labeling

  1. Upon receipt, warehouse staff shall:
    • Verify material name, quantity, supplier details, and CoA.
    • Assign a unique internal receipt number (e.g., RM-2025-045).
    • Affix material status label (Quarantine/Approved/Rejected).
  2. Record details in Annexure-1: Material Receipt Log.

5.2 Storage and Dispensing

  1. Store approved materials in designated temperature-controlled areas.
  2. Issue materials to production only against approved batch manufacturing records (BMR).
  3. Record quantity issued, lot number, and operator initials in Annexure-2: Material Issuance Log.

5.3 Usage Documentation

  1. Production staff shall:
    • Record actual quantity used, time, and stage of process (e.g., media prep, feeding).
    • Use barcode/RFID system (if implemented) to log usage.
    • Cross-check with balance records to avoid duplication or omission.
  2. QA to verify usage against planned requirements.

5.4 Traceability Verification

  1. QA shall perform periodic traceability checks:
    • Backward: From usage back to receipt
    • Forward: From material receipt to all batches it was used in
  2. Use Annexure-3: Traceability Mapping Sheet to capture review outcomes.

5.5 Deviations and Reconciliation

  1. Any discrepancy in usage, excess consumption, or material swap must be reported using deviation management system.
  2. Reconciliation must be completed post-batch and signed by Production and QA.

6. Abbreviations

  • BMR: Batch Manufacturing Record
  • CoA: Certificate of Analysis
  • QA: Quality Assurance
  • GMP: Good Manufacturing Practice

7. Documents

  1. Material Receipt Log – Annexure-1
  2. Material Issuance Log – Annexure-2
  3. Traceability Mapping Sheet – Annexure-3

8. References

  • 21 CFR Part 211 – Subpart E: Control of Components and Drug Product Containers and Closures
  • EU GMP Chapter 5 – Production
  • WHO TRS 986 Annex 2 – GMP for Biologics

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Material Receipt Log

Date Material Name Vendor Lot No. Qty Label No.
04/05/2025 CHO Feed A Thermo Fisher TF-4587 25 kg RM-2025-045

Annexure-2: Material Issuance Log

Date Batch No. Material Issued Qty Used By
04/05/2025 BS-UP-078 CHO Feed A 12 kg Ajay Verma

Annexure-3: Traceability Mapping Sheet

Material Receipt ID Batch Used In Qty Used Verified By
CHO Feed A RM-2025-045 BS-UP-078 12 kg Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Barcode and deviation handling added Audit Compliance
See also  Biosimilars: SOP for Validation of Upstream Processes - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Analytical Method Development: SOP for NIR Method Development for In-Process Testing – V 2.0
Next Post: Sterile Injectable Manufacturing: SOP for Visual Inspection of Packaging Materials – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version